Stockholm, Sweden Saturday, February 22, 2025, 09:00 Hrs [IST] ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.

Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...

We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

This contract has experienced an incredible rally since Jan. 22, however, the forward curve is pointing sharply downwards ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...

Continued strong commercial execution of the OGSIVEO launch in the U.S. with fourth quarter and full-year 2024 U.S. net product revenue for OGSIVEO of $61.5 million and $172.0 million, respectively.